A randomized controlled trial of two hepatitis a vaccine doses among adolescents with juvenile idiopathic arthritis and Crohn's disease on immunosuppressive therapy: a pilot study

Racheal Githumbi; Susan Kuhn; Carla Osiowy; Jacqueline Day; Jennifer C C deBruyn; Marvin J Fritzler; Nicole A Johnson; Otto Vanderkooi; Heinrike Schmeling

doi:10.1093/jtm/taae065

A randomized controlled trial of two hepatitis a vaccine doses among adolescents with juvenile idiopathic arthritis and Crohn's disease on immunosuppressive therapy: a pilot study

J Travel Med. 2024 Apr 23:taae065. doi: 10.1093/jtm/taae065. Online ahead of print.

Authors

Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jacqueline Day², Jennifer C C deBruyn¹, Marvin J Fritzler³, Nicole A Johnson¹, Otto Vanderkooi¹, Heinrike Schmeling¹

Affiliations

¹ Department of Pediatrics, Cumming School of Medicine, University of Calgary.
² National Microbiology Laboratory, Public Health Agency of Canada.
³ Department of Medicine, Cumming School of Medicine, University of Calgary.

PMID: 38652172
DOI: 10.1093/jtm/taae065

Abstract

This pilot randomized controlled trial assessed the immunogenicity of paediatric versus adult Hepatitis A vaccine doses in immunosuppressed adolescents (12-15 years) with Juvenile Idiopathic Arthritis and Crohn's Disease. The study aimed to assess if a single, higher dose provides better immunogenicity, particularly beneficial before travel.

Keywords: crohn’s disease; hepatis A vaccine; immunosuppression; juvenile idiopathic arthritis; randomized controlled trial.